Clarity matters.
Traditional breast cancer biomarker testing methods are challenging. Technical and observer variability plus the lack of standardization can lead to inaccurate results.
Xpert® Breast Cancer STRAT41 is provides you with clear and consistent ER/PR/HER2/Ki-67 results from unstained FFPE sections in less than 2 hours with minimum hands on time.2
Introducing the Xpert® Breast Cancer STRAT4 Test:2
- Reduced subjectivity compared to conventional IHC and FISH
- Excellent concordance with recognized standards
- Easy to interpret results
- External controls available
Cepheid Oncology Business Unit Description
Cepheid’s innovative oncology program offers a growing menu of molecular diagnostic tests that currently focuses on cancers of the breast, bladder, and blood. Leveraging Cepheid’s proven molecular diagnostics platform, our oncology products deliver on-site, on-demand, accurate, and reliable results. The pioneering mindset of our team is bolstered by Cepheid’s strong molecular biology capabilities, extensive global infrastructure, and an unwavering commitment to scientific rigor. Our vision is to deliver life-changing technology to physicians and their cancer patients globally.
References
1CE-IVD. In Vitro Diagnostic Medical Device. Not available in all countries. Not available in the United States.
2Xpert® Breast Cancer STRAT4 Package Insert. Sunnyvale, USA. 2017.
Want to learn more about the Xpert® Breast Cancer STRAT4 test?
Complete the form below and a member of our team will contact you.